Dapsone-associateD methaemoglobinaemia
Anaesthesia and Intensive Care, Vol. 38, No. 6, November 2010 of methaemoglobinaemia and to identify any contributing factors (e.g. medications).
In this article we present the results of our study and provide a brief review of the pathogenesis of this condition in an attempt to explain the comparatively high incidence of methaemoglobinaemia in our patients.
MATERIALS AND METHODS

Study design
Single-centre retrospective observational study.
Inclusion criteria
Patients meeting all of the following criteria were reviewed: 1) adult patients (age ≥18 years); 2) haematologic malignancy (acute leukaemia and lymphoma) receiving dapsone for Pneumocystis PJP prophylaxis between 1 January and 31 December 2008; 3) who had co-oximetry tests; and 4) those with methaemoglobinaemia, defined as a MetHb level ≥1.5% in hospitalised patients 5 .
Exclusion criteria
Age <18 years and those patients with haematologic malignancy on dapsone who did not have a co-oximetry test performed.
Some patients had serial co-oximetry tests performed over the course of hours or days. The peak MetHb percentage for each patient, considered the most clinically relevant, was recorded. All pertinent information was extracted, including concomitant medications and their possible interactions with dapsone. Naranjo probability scale 8 was employed to estimate the probability of dapsone adverse drug reaction.
Case reports
Thirteen patients had elevated MetHb levels. Two of these patients who required ICU support are briefly described -symptomatic methaemoglobinaemia was diagnosed in one patient but overlooked in the other (Table 1) .
RESULTS
A total of 34 patients with haematologic malignancy received dapsone 100 mg daily for PJP prophylaxis during the study period ( Figure 1 ). The majority of patients had leukaemia (76.5%) ( Table 2 ). Eighteen patients had co-oximetry studies done and of these, 13 (64.7%) had MetHb levels ≥1.5% with four patients developing symptomatic methaemoglobinaemia. Eight of these patients required ICU support.
All patients (n=13) were anaemic with a mean Hb of 83.9 g/l (range 59 to 111 g/l) at the time of the elevated MetHb, with female patients relatively more anaemic (79.8 vs 88.7 g/l) ( Table 3) .
Methaemoglobinaemia was appropriately managed with cessation of dapsone and administration of methylene blue in three of the four symptomatic patients 9 . Raised MetHb levels (mean 3.6%; range 1.9 to 10.4%) were identified table 1
Case reports
Thirteen patients had elevated MetHb levels. Two of these patients who required ICU support are briefly described: symptomatic methaemoglobinaemia was diagnosed in one but overlooked in the other. Case 1: A 74-year-old woman was newly diagnosed with acute myeloid leukaemia M4 (AML). Her past medical history included stable ischaemic heart disease, peptic ulcer disease, diet-controlled type 2 diabetes mellitus and hypertension, which were adequately controlled with isosorbide mononitrate, omeprazole, atenolol and atorvastatin. She did not have any drug allergies. Dapsone was commenced for PJP prophylaxis at the time of chemotherapy (cytarabine and idarubicin) commencement. Chemotherapy was initially well tolerated, however on day 9 she developed neutropenic enterocolitis and was commenced on empiric antibiotics. On day 12, she suddenly developed respiratory distress with increasing O 2 requirements. Chest X-ray demonstrated mild pulmonary congestion. Her oxygenation deteriorated with pulse oximetry readings (SpO 2 ) consistently below 90% despite diuresis and increasing FiO 2 requirements. Co-oximetry studies showed severe methaemoglobinaemia with a level of 26.8%, Hb of 108 g/l and a measured fractional saturation of O 2 of 71.8%. Dapsone was ceased immediately and the patient transferred to ICU where she was managed with non-invasive ventilatory support. Methaemoglobinaemia was rapidly reversed by the intravenous administration of methylene blue. Non-invasive ventilation was weaned to low flow O 2 within 1 hour. She was discharged to the haematology ward within 36 hours. Case 2: A 37-year-old woman was newly diagnosed AML (M2) when she presented with toothache and two-month history of malaise and easy bruising. She did not have any significant past medical history or drug allergies and was not on any regular medications. The patient was pancytopenic on diagnosis, requiring blood products. Chemotherapy (idarubicin, cyarabine and etoposide) was commenced and dapsone was included in the prophylactic regimen. Empiric antibiotics were commenced on day 7 when she became febrile. The following day, she developed Pseudomonas aeruginosa septicaemia with respiratory distress and deteriorating oxygenation. She was managed supportively in ICU for 8 days, which included mechanical ventilation and intravenous antibiotics. Retrospective co-oximetry analysis revealed a moderate methaemoglobinaemia (level of 10.4%), which was overlooked and no specific treatment instituted. Due to chest X-ray images suggestive of PJP pneumonia, dapsone was ceased and commenced to treatment dose of trimethoprimsulfamethoxazole.
ICU=intensive care unit, AML=acute myeloid leukaemia, M2, M4=subtypes of AML, based on French-American-British classification, PJP=Pneumocystis jiroveci pneumonia. in the remaining 10 patients during the retrospective review of co-oximetry results. The mean peak ± standard deviation of MetHb level was 7.84±8.04%. Overall, the mean time to onset of methaemoglobinaemia was 11.8 days (median 11 days; range 4 to 18 days). Fractional saturation of O 2 10 , the oxyhaemoglobin concentration expressed as a percentage of total haemoglobin concentration, was significantly reduced in patients with symptomatic methaemoglobinaemia (mean 78%) (Tables 2 and 3 ).
In our cohort of patients, only 47% (16/34) were tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency but were all within normal range, even the two patients with symptomatic methaemoglobinaemia. Evidence of haemolysis (fragmental cells and spherocytes in the peripheral film) was difficult to assess as all patients were transfused with blood products to support their pancytopenia; however the haemolytic screen, which consisted of Coomb's test, haptoglobin level, indirect bilirubin and reticulocyte count, was inconclusive.
Eight patients had evidence of bacteraemia and one had candidaemia.
DISCUSSION
Pneumocystis jiroveci is an atypical fungus that causes severe and potentially life-threatening pneumonia in immunocompromised patients and prophylaxis is desirable in this group of patients. A meta-analysis of randomised trials for PJP prophylaxis in immunocompromised adult patients without human immunodeficiency virus infection concluded that prophylaxis is warranted when the risk of PJP is greater than 3.5% 11 . Patients at our institution experienced a higher incidence of PJP (Schwarer et al; unpublished observation), thus all patients receiving chemotherapy for haematologic malignancies were usually prescribed PJP prophylaxis.
Trimethoprim-sulfamethoxazole is deemed first-line prophylactic agent 7, 12, 13 , however myelosuppression and neutropenia are common adverse effects, particularly when used in combination with other chemotherapeutic myelosuppressive agents 14, 15 . As myelosuppression is inevitable in patients with haematological malignancies, trimethoprimsulfamethoxazole is best avoided. Dapsone is nonmyelosuppressive and considered a second-line agent for PJP prophylaxis 7, 16 . Methaemoglobinaemia and haemolytic anaemia are known adverse effects of dapsone. A recent study listed dapsone as the most common offending agent 5 . Identification of patients with methaemoglobinaemia was based on the results of the cooximetry test (considered as gold standard in the diagnosis of dyshaemoglobinaemias 17 ). However, co-oximetry was performed in only 18 of the 34 patients (53%) surveyed. Based on data from these 18 patients, the incidence of methaemoglobinaemia (levels ≥1.5%) was 72.2%. Of the patients with raised MetHb levels, 30.8% were symptomatic between four and 18 days (median 11.8 days) of commencement of dapsone.
In our study, all patients with elevated MetHb levels were anaemic, as would be expected from patients with haematological malignancies or as a consequence of their treatment. A review of the medication regimens showed some common features, mainly the use of antifungal agents in all patients (for prophylaxis or treatment) and high-dose corticosteroids.
The true incidence of dapsone-associated methaemoglobinaemia has not been widely studied. Previous reports of clinically significant dapsonerelated adverse events have typically been associated with higher doses of the medication. The literature estimated incidence ranged between 4 to 13% in adults 18 and around 20% in children 19 , on prophylactic doses of dapsone who developed some degree of haemolytic anaemia or methaemoglobinaemia. This was significantly lower when compared to our study. The low rate of co-oximetry testing might have underestimated the likelihood/potential for an asymptomatic raised MetHb.
The average duration of dapsone prophylaxis prior to diagnosis of methaemoglobinaemia in patients with haematological malignancies and solid tumours was about seven weeks (range 3.5 to 10 weeks) 18, 19 . Our cohort had a markedly earlier onset of raised MetHb levels (11.8 days; range 4 to 18 days) ( Table 4 ).
There were various possible contributing factors that caused a higher incidence and earlier onset of methaemoglobinaemia in our patient population, such as anaemia, sepsis and concomitant drug therapy.
In the literature, dapsone-associated adverse events were usually dose-dependent and were more severe in patients with underlying comorbidities, including anaemia, cardiopulmonary disease or deficiency of G6PD 20 . One of our patients developed symptomatic methaemoglobinaemia had stable ischaemic heart disease. Despite being a known risk factor for acquired methaemoglobinaemia in patients of dapsone 21 , G6PD deficiency was not tested in all our patients and hence was difficult to comment about the patients who were not tested.
Published reports suggest that MetHb levels were significantly higher in critically ill septic patients 22 . Even though these patients were neutropenic, eight patients had documented infections. However, sepsis was a less likely contributor of methaemoglobinaemia, as the timing of raised MetHb levels did not correlate with the severity of sepsis.
Previous reports suggest that these adverse events occur at the peak of immunosuppression and this was definitely applicable to our patients.
Anaemic patients may be more sensitive to symptoms of methaemoglobinaemia because of their lower functional Hb reserve. All of our patients were anaemic, with worsening of symptoms with the onset of methaemoglobinaemia. The fractional O 2 saturation was significantly reduced in patients with symptomatic when compared with asymptomatic methaemoglobinaemia (78 vs 92.6%), explaining why these patients were distressed and required high oxygen requirements.
Based on the pharmacokinetic data, dapsone may interact with other drugs such as corticosteroids and antifungal agents (both commonly used in cancer patients), thus increasing the potential for MetHb formation. Different chemotherapeutic regimens were used in our patients; however, none were known to increase MetHb formation.
Dapsone is metabolised in the liver via acetylation or N-hydroxylation ( Figure 2 ). Dapsone hydroxylamine, produced by N-hydroxylation via cytochrome P-450 enzymes, is a potentially toxic metabolite causing methaemoglobinaemia and Heinz body haemolytic anaemia 23 . On the other hand, acetylation by N-acetyltransferase yields nontoxic metabolites. However, it remains controversial whether acetylation polymorphism affects dapsone toxicity. Toxicity has not been associated with dapsone plasma levels but rather with N-acetylation and N-hydroxylation capacities, the latter being mediated via cytochrome P-450 system 24 . Patients who are slow acetylators or fast hydroxylators have a greater risk of developing methaemoglobinaemia 24 . However, tests to determine acetylator status are not readily available and expensive. Inducers of CYP-2C9 and CYP-2C19 could theoretically increase toxicity by increasing production of the dapsone hydroxylamine metabolite ( Table 5 ). All patients in our cohort were on voriconazole or fluconazole, both known to induce CYP-2C9, and five patients were on high-dose steroids (≥1 mg/kg of prednisolone or equivalent), which induce CYP-2C19 25 . These drugs could potentially increase the production of toxic dapsone metabolites and hence causing methaemoglobinaemia 26 .
There are a number of limitations to this study. Co-oximetry was not performed in all patients so the true incidence of methaemoglobinaemia may be underestimated. There are however, very few suitable alternatives to PJP prophylaxis in this group of patients. Increasing use of aggressive chemotherapy requires the need for PJP prophylaxis and hence is important for future prospective studies to identify the risk factors.
CONCLUSION AND RECOMMENDATIONS
Dapsone-associated acquired methaemoglobinaemia is a treatable condition that causes significant morbidity, even mortality. Given the relative frequency of dapsone-associated adverse events in patients with haematologic malignancies, it is important to consider this early in individuals with unexplained respiratory insufficiency. Patients with leukaemia may be particularly at risk due to underlying anaemia, immunosuppression and potential drug interactions, particularly corticosteroids and 'azole' antifungal agents, common adjuncts to contemporary chemotherapeutic regimens. We suggest the following recommendations: 1. The diagnosis of methaemoglobinaemia should be suspected in all patients on dapsone therapy with unexplained cyanosis and respiratory symptoms, and co-oximetry should be performed promptly. 2. Treatment with methylene blue may be required in symptomatic patients.
Management in ICU is not usually required
if the condition is appropriately identified and managed. 4. G6PD deficiency should be tested in all patients prior to dapsone commencement as methylene blue may be ineffective and potentially dangerous in these patients 27 .
Drugs which inhibit cytochrome P-450 should be
used with caution in patients receiving dapsone. However, it is important to consider an alternative agent for PJP prophylaxis in patients where these agents are obligatory. 
